nodes	percent_of_prediction	percent_of_DWPC	metapath
Bezafibrate—CYP1A1—Dacarbazine—muscle cancer	0.326	0.49	CbGbCtD
Bezafibrate—SLCO1B1—Methotrexate—muscle cancer	0.144	0.216	CbGbCtD
Bezafibrate—CYP2C8—Etoposide—muscle cancer	0.092	0.138	CbGbCtD
Bezafibrate—CYP3A4—Vincristine—muscle cancer	0.0407	0.0612	CbGbCtD
Bezafibrate—CYP3A4—Etoposide—muscle cancer	0.0373	0.0561	CbGbCtD
Bezafibrate—CYP3A4—Doxorubicin—muscle cancer	0.0254	0.0383	CbGbCtD
Bezafibrate—PPARG—hindlimb—muscle cancer	0.0156	0.108	CbGeAlD
Bezafibrate—PPARG—appendage—muscle cancer	0.0133	0.0923	CbGeAlD
Bezafibrate—PPARG—Teniposide—Etoposide—muscle cancer	0.00984	1	CbGdCrCtD
Bezafibrate—PPARA—embryo—muscle cancer	0.00806	0.0557	CbGeAlD
Bezafibrate—PPARA—smooth muscle tissue—muscle cancer	0.00634	0.0438	CbGeAlD
Bezafibrate—PPARA—renal system—muscle cancer	0.0061	0.0422	CbGeAlD
Bezafibrate—PPARD—tendon—muscle cancer	0.00559	0.0386	CbGeAlD
Bezafibrate—PPARD—Pyruvate metabolism and Citric Acid (TCA) cycle—FH—muscle cancer	0.00522	0.103	CbGpPWpGaD
Bezafibrate—PPARD—vagina—muscle cancer	0.00519	0.0358	CbGeAlD
Bezafibrate—PPARD—head—muscle cancer	0.00479	0.0331	CbGeAlD
Bezafibrate—PPARD—testis—muscle cancer	0.00463	0.032	CbGeAlD
Bezafibrate—PPARG—embryo—muscle cancer	0.00443	0.0306	CbGeAlD
Bezafibrate—HMGCR—smooth muscle tissue—muscle cancer	0.00422	0.0292	CbGeAlD
Bezafibrate—PPARA—head—muscle cancer	0.00408	0.0282	CbGeAlD
Bezafibrate—HMGCR—renal system—muscle cancer	0.00406	0.0281	CbGeAlD
Bezafibrate—PPARA—testis—muscle cancer	0.00394	0.0273	CbGeAlD
Bezafibrate—SLCO1B1—renal system—muscle cancer	0.00389	0.0269	CbGeAlD
Bezafibrate—HMGCR—cardiac atrium—muscle cancer	0.00364	0.0251	CbGeAlD
Bezafibrate—PPARG—smooth muscle tissue—muscle cancer	0.00348	0.0241	CbGeAlD
Bezafibrate—PPARG—renal system—muscle cancer	0.00335	0.0232	CbGeAlD
Bezafibrate—HMGCR—tendon—muscle cancer	0.00317	0.0219	CbGeAlD
Bezafibrate—HMGCR—bone marrow—muscle cancer	0.00307	0.0212	CbGeAlD
Bezafibrate—HMGCR—vagina—muscle cancer	0.00294	0.0203	CbGeAlD
Bezafibrate—HMGCR—head—muscle cancer	0.00272	0.0188	CbGeAlD
Bezafibrate—HMGCR—testis—muscle cancer	0.00262	0.0181	CbGeAlD
Bezafibrate—PPARG—tendon—muscle cancer	0.00262	0.0181	CbGeAlD
Bezafibrate—PPARG—bone marrow—muscle cancer	0.00254	0.0175	CbGeAlD
Bezafibrate—PPARG—vagina—muscle cancer	0.00243	0.0168	CbGeAlD
Bezafibrate—Balsalazide—PTGS2—muscle cancer	0.00242	0.694	CrCbGaD
Bezafibrate—PPARD—Ectoderm Differentiation—PAX3—muscle cancer	0.00239	0.0469	CbGpPWpGaD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—PAX3—muscle cancer	0.00236	0.0462	CbGpPWpGaD
Bezafibrate—PPARG—head—muscle cancer	0.00224	0.0155	CbGeAlD
Bezafibrate—CYP2C8—renal system—muscle cancer	0.00221	0.0153	CbGeAlD
Bezafibrate—Myositis—Doxorubicin—muscle cancer	0.0022	0.0174	CcSEcCtD
Bezafibrate—PPARG—testis—muscle cancer	0.00217	0.015	CbGeAlD
Bezafibrate—Phosphatase alkaline increased—Etoposide—muscle cancer	0.00208	0.0165	CcSEcCtD
Bezafibrate—CYP1A1—renal system—muscle cancer	0.00204	0.0141	CbGeAlD
Bezafibrate—PPARD—The citric acid (TCA) cycle and respiratory electron transport—FH—muscle cancer	0.00203	0.0398	CbGpPWpGaD
Bezafibrate—Liver function test abnormal—Dactinomycin—muscle cancer	0.00192	0.0152	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00188	0.0149	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.00188	0.0149	CcSEcCtD
Bezafibrate—CYP1A1—cardiac atrium—muscle cancer	0.00183	0.0126	CbGeAlD
Bezafibrate—Transaminases increased—Doxorubicin—muscle cancer	0.00177	0.014	CcSEcCtD
Bezafibrate—Serum creatinine increased—Doxorubicin—muscle cancer	0.00175	0.0139	CcSEcCtD
Bezafibrate—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.00173	0.0137	CcSEcCtD
Bezafibrate—Pancytopenia—Dactinomycin—muscle cancer	0.00171	0.0135	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00168	0.0133	CcSEcCtD
Bezafibrate—Muscular weakness—Vincristine—muscle cancer	0.00164	0.013	CcSEcCtD
Bezafibrate—CYP2C8—vagina—muscle cancer	0.0016	0.0111	CbGeAlD
Bezafibrate—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.00159	0.0126	CcSEcCtD
Bezafibrate—PPARG—Transcription factor regulation in adipogenesis—FOXO1—muscle cancer	0.00157	0.0308	CbGpPWpGaD
Bezafibrate—Pancytopenia—Vincristine—muscle cancer	0.00153	0.0121	CcSEcCtD
Bezafibrate—PPARD—Ectoderm Differentiation—DMD—muscle cancer	0.00152	0.0298	CbGpPWpGaD
Bezafibrate—CYP3A4—renal system—muscle cancer	0.0015	0.0104	CbGeAlD
Bezafibrate—Erectile dysfunction—Vincristine—muscle cancer	0.00148	0.0117	CcSEcCtD
Bezafibrate—CYP1A1—vagina—muscle cancer	0.00148	0.0102	CbGeAlD
Bezafibrate—Photosensitivity reaction—Vincristine—muscle cancer	0.00147	0.0116	CcSEcCtD
Bezafibrate—PPARA—Transcriptional regulation of white adipocyte differentiation—MED12—muscle cancer	0.00146	0.0287	CbGpPWpGaD
Bezafibrate—Pharyngitis—Dactinomycin—muscle cancer	0.00143	0.0113	CcSEcCtD
Bezafibrate—CYP2C8—testis—muscle cancer	0.00143	0.00988	CbGeAlD
Bezafibrate—Acute coronary syndrome—Vincristine—muscle cancer	0.00141	0.0112	CcSEcCtD
Bezafibrate—Myocardial infarction—Vincristine—muscle cancer	0.00141	0.0111	CcSEcCtD
Bezafibrate—CYP1A1—head—muscle cancer	0.00137	0.00944	CbGeAlD
Bezafibrate—Erythema multiforme—Dactinomycin—muscle cancer	0.00136	0.0108	CcSEcCtD
Bezafibrate—Cramp muscle—Etoposide—muscle cancer	0.00136	0.0108	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00136	0.0108	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00133	0.0105	CcSEcCtD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—MYOD1—muscle cancer	0.0013	0.0255	CbGpPWpGaD
Bezafibrate—Alopecia—Dactinomycin—muscle cancer	0.00127	0.0101	CcSEcCtD
Bezafibrate—Urinary tract disorder—Vincristine—muscle cancer	0.00127	0.0101	CcSEcCtD
Bezafibrate—Urethral disorder—Vincristine—muscle cancer	0.00126	0.01	CcSEcCtD
Bezafibrate—Erythema—Dactinomycin—muscle cancer	0.00125	0.00994	CcSEcCtD
Bezafibrate—Pancytopenia—Etoposide—muscle cancer	0.00124	0.0098	CcSEcCtD
Bezafibrate—HMGCR—PPARA activates gene expression—MED12—muscle cancer	0.0012	0.0236	CbGpPWpGaD
Bezafibrate—HMGCR—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.00118	0.0231	CbGpPWpGaD
Bezafibrate—Anaemia—Dactinomycin—muscle cancer	0.00116	0.00918	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00115	0.00912	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Etoposide—muscle cancer	0.00114	0.00907	CcSEcCtD
Bezafibrate—Myocardial infarction—Etoposide—muscle cancer	0.00114	0.00902	CcSEcCtD
Bezafibrate—Alopecia—Vincristine—muscle cancer	0.00114	0.00901	CcSEcCtD
Bezafibrate—PPARA—PPARA activates gene expression—MED12—muscle cancer	0.0011	0.0216	CbGpPWpGaD
Bezafibrate—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.00108	0.00853	CcSEcCtD
Bezafibrate—PPARA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.00108	0.0211	CbGpPWpGaD
Bezafibrate—Myalgia—Dactinomycin—muscle cancer	0.00107	0.00846	CcSEcCtD
Bezafibrate—Indomethacin—PTGS2—muscle cancer	0.00106	0.306	CrCbGaD
Bezafibrate—PPARG—Transcriptional regulation of white adipocyte differentiation—MED12—muscle cancer	0.00105	0.0206	CbGpPWpGaD
Bezafibrate—PPARD—Adipogenesis—HMGA1—muscle cancer	0.00105	0.0205	CbGpPWpGaD
Bezafibrate—Anaemia—Vincristine—muscle cancer	0.00104	0.00821	CcSEcCtD
Bezafibrate—Urinary tract disorder—Etoposide—muscle cancer	0.00103	0.00816	CcSEcCtD
Bezafibrate—Photosensitivity—Methotrexate—muscle cancer	0.00103	0.00815	CcSEcCtD
Bezafibrate—Urethral disorder—Etoposide—muscle cancer	0.00102	0.0081	CcSEcCtD
Bezafibrate—Infection—Dactinomycin—muscle cancer	0.00102	0.00806	CcSEcCtD
Bezafibrate—Thrombocytopenia—Dactinomycin—muscle cancer	0.001	0.00794	CcSEcCtD
Bezafibrate—Erythema multiforme—Etoposide—muscle cancer	0.000986	0.00781	CcSEcCtD
Bezafibrate—Renal failure acute—Methotrexate—muscle cancer	0.000978	0.00775	CcSEcCtD
Bezafibrate—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000974	0.0191	CbGpPWpGaD
Bezafibrate—Myalgia—Vincristine—muscle cancer	0.000954	0.00756	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000932	0.00739	CcSEcCtD
Bezafibrate—Alopecia—Etoposide—muscle cancer	0.000921	0.0073	CcSEcCtD
Bezafibrate—PPARA—Developmental Biology—MYF6—muscle cancer	0.000909	0.0178	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—MYF5—muscle cancer	0.000909	0.0178	CbGpPWpGaD
Bezafibrate—Infection—Vincristine—muscle cancer	0.000908	0.0072	CcSEcCtD
Bezafibrate—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.000899	0.00712	CcSEcCtD
Bezafibrate—Thrombocytopenia—Vincristine—muscle cancer	0.000895	0.00709	CcSEcCtD
Bezafibrate—Photosensitivity—Doxorubicin—muscle cancer	0.00089	0.00705	CcSEcCtD
Bezafibrate—Pain—Dactinomycin—muscle cancer	0.000875	0.00694	CcSEcCtD
Bezafibrate—Vascular purpura—Doxorubicin—muscle cancer	0.000874	0.00692	CcSEcCtD
Bezafibrate—Muscle spasms—Etoposide—muscle cancer	0.000873	0.00691	CcSEcCtD
Bezafibrate—Eczema—Doxorubicin—muscle cancer	0.00087	0.00689	CcSEcCtD
Bezafibrate—Renal failure acute—Doxorubicin—muscle cancer	0.000847	0.00671	CcSEcCtD
Bezafibrate—Anaemia—Etoposide—muscle cancer	0.000839	0.00665	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000837	0.00663	CcSEcCtD
Bezafibrate—Liver function test abnormal—Methotrexate—muscle cancer	0.000833	0.0066	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000833	0.0066	CcSEcCtD
Bezafibrate—Insomnia—Vincristine—muscle cancer	0.000827	0.00655	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000813	0.00644	CcSEcCtD
Bezafibrate—HMGCR—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000811	0.0159	CbGpPWpGaD
Bezafibrate—Purpura—Doxorubicin—muscle cancer	0.000811	0.00643	CcSEcCtD
Bezafibrate—Abdominal pain—Dactinomycin—muscle cancer	0.000809	0.00641	CcSEcCtD
Bezafibrate—PPARA—Adipogenesis—HMGA1—muscle cancer	0.000798	0.0156	CbGpPWpGaD
Bezafibrate—PPARG—PPARA activates gene expression—MED12—muscle cancer	0.000789	0.0155	CbGpPWpGaD
Bezafibrate—Pain—Vincristine—muscle cancer	0.000782	0.0062	CcSEcCtD
Bezafibrate—Constipation—Vincristine—muscle cancer	0.000782	0.0062	CcSEcCtD
Bezafibrate—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.000772	0.0151	CbGpPWpGaD
Bezafibrate—Migraine—Doxorubicin—muscle cancer	0.000769	0.0061	CcSEcCtD
Bezafibrate—Hypersensitivity—Dactinomycin—muscle cancer	0.000754	0.00598	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Vincristine—muscle cancer	0.000748	0.00593	CcSEcCtD
Bezafibrate—PPARA—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000742	0.0146	CbGpPWpGaD
Bezafibrate—Pancytopenia—Methotrexate—muscle cancer	0.000741	0.00587	CcSEcCtD
Bezafibrate—Infection—Etoposide—muscle cancer	0.000736	0.00583	CcSEcCtD
Bezafibrate—Blood creatinine increased—Doxorubicin—muscle cancer	0.000732	0.0058	CcSEcCtD
Bezafibrate—Thrombocytopenia—Etoposide—muscle cancer	0.000725	0.00575	CcSEcCtD
Bezafibrate—Abdominal pain—Vincristine—muscle cancer	0.000723	0.00573	CcSEcCtD
Bezafibrate—Liver function test abnormal—Doxorubicin—muscle cancer	0.000722	0.00572	CcSEcCtD
Bezafibrate—Erectile dysfunction—Methotrexate—muscle cancer	0.000719	0.00569	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Methotrexate—muscle cancer	0.000712	0.00564	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000704	0.00558	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000704	0.00558	CcSEcCtD
Bezafibrate—Diarrhoea—Dactinomycin—muscle cancer	0.0007	0.00555	CcSEcCtD
Bezafibrate—PPARD—Adipogenesis—FOXO1—muscle cancer	0.000694	0.0136	CbGpPWpGaD
Bezafibrate—Gastritis—Doxorubicin—muscle cancer	0.000692	0.00548	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00069	0.00547	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000689	0.00546	CcSEcCtD
Bezafibrate—Muscular weakness—Doxorubicin—muscle cancer	0.000689	0.00546	CcSEcCtD
Bezafibrate—Influenza—Doxorubicin—muscle cancer	0.000676	0.00535	CcSEcCtD
Bezafibrate—Hypersensitivity—Vincristine—muscle cancer	0.000674	0.00534	CcSEcCtD
Bezafibrate—PPARG—Developmental Biology—MYF5—muscle cancer	0.000651	0.0128	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—MYF6—muscle cancer	0.000651	0.0128	CbGpPWpGaD
Bezafibrate—Bronchitis—Doxorubicin—muscle cancer	0.00065	0.00515	CcSEcCtD
Bezafibrate—Rash—Dactinomycin—muscle cancer	0.000645	0.00511	CcSEcCtD
Bezafibrate—Pancytopenia—Doxorubicin—muscle cancer	0.000642	0.00508	CcSEcCtD
Bezafibrate—Pain—Etoposide—muscle cancer	0.000633	0.00502	CcSEcCtD
Bezafibrate—Constipation—Etoposide—muscle cancer	0.000633	0.00502	CcSEcCtD
Bezafibrate—Diarrhoea—Vincristine—muscle cancer	0.000626	0.00496	CcSEcCtD
Bezafibrate—CYP1A1—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000621	0.0122	CbGpPWpGaD
Bezafibrate—Pharyngitis—Methotrexate—muscle cancer	0.00062	0.00491	CcSEcCtD
Bezafibrate—Urinary tract disorder—Methotrexate—muscle cancer	0.000617	0.00489	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000617	0.00489	CcSEcCtD
Bezafibrate—Urethral disorder—Methotrexate—muscle cancer	0.000612	0.00485	CcSEcCtD
Bezafibrate—Nausea—Dactinomycin—muscle cancer	0.000608	0.00482	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Etoposide—muscle cancer	0.000606	0.0048	CcSEcCtD
Bezafibrate—Dizziness—Vincristine—muscle cancer	0.000605	0.00479	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000597	0.00473	CcSEcCtD
Bezafibrate—Erythema multiforme—Methotrexate—muscle cancer	0.000591	0.00468	CcSEcCtD
Bezafibrate—Urticaria—Etoposide—muscle cancer	0.000588	0.00466	CcSEcCtD
Bezafibrate—Abdominal pain—Etoposide—muscle cancer	0.000586	0.00464	CcSEcCtD
Bezafibrate—PPARA—Developmental Biology—MYOG—muscle cancer	0.000586	0.0115	CbGpPWpGaD
Bezafibrate—Rash—Vincristine—muscle cancer	0.000577	0.00457	CcSEcCtD
Bezafibrate—Dermatitis—Vincristine—muscle cancer	0.000576	0.00456	CcSEcCtD
Bezafibrate—Headache—Vincristine—muscle cancer	0.000573	0.00454	CcSEcCtD
Bezafibrate—PPARG—Adipogenesis—HMGA1—muscle cancer	0.000572	0.0112	CbGpPWpGaD
Bezafibrate—Alopecia—Methotrexate—muscle cancer	0.000552	0.00437	CcSEcCtD
Bezafibrate—Hypersensitivity—Etoposide—muscle cancer	0.000546	0.00432	CcSEcCtD
Bezafibrate—Erythema—Methotrexate—muscle cancer	0.000544	0.00431	CcSEcCtD
Bezafibrate—Nausea—Vincristine—muscle cancer	0.000543	0.0043	CcSEcCtD
Bezafibrate—Pharyngitis—Doxorubicin—muscle cancer	0.000537	0.00425	CcSEcCtD
Bezafibrate—Urinary tract disorder—Doxorubicin—muscle cancer	0.000534	0.00423	CcSEcCtD
Bezafibrate—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000532	0.0104	CbGpPWpGaD
Bezafibrate—Urethral disorder—Doxorubicin—muscle cancer	0.00053	0.0042	CcSEcCtD
Bezafibrate—PPARA—Adipogenesis—FOXO1—muscle cancer	0.000528	0.0104	CbGpPWpGaD
Bezafibrate—Pruritus—Etoposide—muscle cancer	0.000524	0.00415	CcSEcCtD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000512	0.0101	CbGpPWpGaD
Bezafibrate—Erythema multiforme—Doxorubicin—muscle cancer	0.000511	0.00405	CcSEcCtD
Bezafibrate—Diarrhoea—Etoposide—muscle cancer	0.000507	0.00402	CcSEcCtD
Bezafibrate—Anaemia—Methotrexate—muscle cancer	0.000502	0.00398	CcSEcCtD
Bezafibrate—Dizziness—Etoposide—muscle cancer	0.00049	0.00388	CcSEcCtD
Bezafibrate—Alopecia—Doxorubicin—muscle cancer	0.000478	0.00379	CcSEcCtD
Bezafibrate—Erythema—Doxorubicin—muscle cancer	0.000471	0.00373	CcSEcCtD
Bezafibrate—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—muscle cancer	0.00047	0.00923	CbGpPWpGaD
Bezafibrate—Rash—Etoposide—muscle cancer	0.000467	0.0037	CcSEcCtD
Bezafibrate—Dermatitis—Etoposide—muscle cancer	0.000467	0.0037	CcSEcCtD
Bezafibrate—Headache—Etoposide—muscle cancer	0.000464	0.00368	CcSEcCtD
Bezafibrate—Flatulence—Doxorubicin—muscle cancer	0.000464	0.00368	CcSEcCtD
Bezafibrate—Myalgia—Methotrexate—muscle cancer	0.000463	0.00367	CcSEcCtD
Bezafibrate—PPARD—Generic Transcription Pathway—MED12—muscle cancer	0.000461	0.00905	CbGpPWpGaD
Bezafibrate—Muscle spasms—Doxorubicin—muscle cancer	0.000453	0.00359	CcSEcCtD
Bezafibrate—Infection—Methotrexate—muscle cancer	0.000441	0.00349	CcSEcCtD
Bezafibrate—Nausea—Etoposide—muscle cancer	0.00044	0.00349	CcSEcCtD
Bezafibrate—Anaemia—Doxorubicin—muscle cancer	0.000435	0.00345	CcSEcCtD
Bezafibrate—Thrombocytopenia—Methotrexate—muscle cancer	0.000434	0.00344	CcSEcCtD
Bezafibrate—PPARG—Developmental Biology—MYOG—muscle cancer	0.00042	0.00823	CbGpPWpGaD
Bezafibrate—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000404	0.0032	CcSEcCtD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—CDKN2A—muscle cancer	0.000403	0.0079	CbGpPWpGaD
Bezafibrate—Insomnia—Methotrexate—muscle cancer	0.000401	0.00318	CcSEcCtD
Bezafibrate—Myalgia—Doxorubicin—muscle cancer	0.000401	0.00318	CcSEcCtD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—MDM2—muscle cancer	0.000391	0.00767	CbGpPWpGaD
Bezafibrate—Dyspepsia—Methotrexate—muscle cancer	0.000391	0.00309	CcSEcCtD
Bezafibrate—CYP1A1—PPARA activates gene expression—MED12—muscle cancer	0.000389	0.00763	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000388	0.00761	CbGpPWpGaD
Bezafibrate—Infection—Doxorubicin—muscle cancer	0.000382	0.00302	CcSEcCtD
Bezafibrate—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.000381	0.00747	CbGpPWpGaD
Bezafibrate—Pain—Methotrexate—muscle cancer	0.000379	0.00301	CcSEcCtD
Bezafibrate—PPARG—Adipogenesis—FOXO1—muscle cancer	0.000379	0.00743	CbGpPWpGaD
Bezafibrate—Thrombocytopenia—Doxorubicin—muscle cancer	0.000376	0.00298	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Methotrexate—muscle cancer	0.000363	0.00287	CcSEcCtD
Bezafibrate—PPARA—Developmental Biology—MYOD1—muscle cancer	0.000362	0.0071	CbGpPWpGaD
Bezafibrate—Urticaria—Methotrexate—muscle cancer	0.000352	0.00279	CcSEcCtD
Bezafibrate—PPARA—Generic Transcription Pathway—MED12—muscle cancer	0.000351	0.0069	CbGpPWpGaD
Bezafibrate—Abdominal pain—Methotrexate—muscle cancer	0.000351	0.00278	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00035	0.00277	CcSEcCtD
Bezafibrate—Insomnia—Doxorubicin—muscle cancer	0.000347	0.00275	CcSEcCtD
Bezafibrate—Dyspepsia—Doxorubicin—muscle cancer	0.000338	0.00268	CcSEcCtD
Bezafibrate—PPARA—Developmental Biology—MED12—muscle cancer	0.000331	0.00649	CbGpPWpGaD
Bezafibrate—HMGCR—AMPK Signaling—TP53—muscle cancer	0.00033	0.00648	CbGpPWpGaD
Bezafibrate—Pain—Doxorubicin—muscle cancer	0.000329	0.0026	CcSEcCtD
Bezafibrate—Constipation—Doxorubicin—muscle cancer	0.000329	0.0026	CcSEcCtD
Bezafibrate—Hypersensitivity—Methotrexate—muscle cancer	0.000327	0.00259	CcSEcCtD
Bezafibrate—HMGCR—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000323	0.00634	CbGpPWpGaD
Bezafibrate—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000314	0.00249	CcSEcCtD
Bezafibrate—Pruritus—Methotrexate—muscle cancer	0.000314	0.00249	CcSEcCtD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000308	0.00603	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—FH—muscle cancer	0.000306	0.006	CbGpPWpGaD
Bezafibrate—Urticaria—Doxorubicin—muscle cancer	0.000305	0.00242	CcSEcCtD
Bezafibrate—Abdominal pain—Doxorubicin—muscle cancer	0.000304	0.00241	CcSEcCtD
Bezafibrate—Diarrhoea—Methotrexate—muscle cancer	0.000304	0.00241	CcSEcCtD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000295	0.0058	CbGpPWpGaD
Bezafibrate—Dizziness—Methotrexate—muscle cancer	0.000293	0.00232	CcSEcCtD
Bezafibrate—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—muscle cancer	0.00029	0.00569	CbGpPWpGaD
Bezafibrate—Hypersensitivity—Doxorubicin—muscle cancer	0.000283	0.00224	CcSEcCtD
Bezafibrate—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000282	0.00554	CbGpPWpGaD
Bezafibrate—Rash—Methotrexate—muscle cancer	0.00028	0.00222	CcSEcCtD
Bezafibrate—Dermatitis—Methotrexate—muscle cancer	0.00028	0.00221	CcSEcCtD
Bezafibrate—Headache—Methotrexate—muscle cancer	0.000278	0.0022	CcSEcCtD
Bezafibrate—Pruritus—Doxorubicin—muscle cancer	0.000272	0.00215	CcSEcCtD
Bezafibrate—Nausea—Methotrexate—muscle cancer	0.000264	0.00209	CcSEcCtD
Bezafibrate—Diarrhoea—Doxorubicin—muscle cancer	0.000263	0.00208	CcSEcCtD
Bezafibrate—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000262	0.00515	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—MYOD1—muscle cancer	0.000259	0.00509	CbGpPWpGaD
Bezafibrate—CYP1A1—Tryptophan metabolism—MDM2—muscle cancer	0.000257	0.00505	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—FH—muscle cancer	0.000255	0.005	CbGpPWpGaD
Bezafibrate—Dizziness—Doxorubicin—muscle cancer	0.000254	0.00201	CcSEcCtD
Bezafibrate—PPARG—Generic Transcription Pathway—MED12—muscle cancer	0.000252	0.00494	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.000248	0.00487	CbGpPWpGaD
Bezafibrate—Rash—Doxorubicin—muscle cancer	0.000242	0.00192	CcSEcCtD
Bezafibrate—Dermatitis—Doxorubicin—muscle cancer	0.000242	0.00192	CcSEcCtD
Bezafibrate—Headache—Doxorubicin—muscle cancer	0.000241	0.00191	CcSEcCtD
Bezafibrate—PPARG—Developmental Biology—MED12—muscle cancer	0.000237	0.00465	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000234	0.00458	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—FH—muscle cancer	0.000233	0.00457	CbGpPWpGaD
Bezafibrate—CYP1A1—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000232	0.00456	CbGpPWpGaD
Bezafibrate—Nausea—Doxorubicin—muscle cancer	0.000228	0.00181	CcSEcCtD
Bezafibrate—PPARD—Gene Expression—MED12—muscle cancer	0.000222	0.00436	CbGpPWpGaD
Bezafibrate—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000213	0.00418	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000212	0.00415	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000196	0.00384	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—FOXO1—muscle cancer	0.000182	0.00356	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000176	0.00346	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—MED12—muscle cancer	0.000173	0.00339	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—MED12—muscle cancer	0.000169	0.00332	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—FH—muscle cancer	0.000167	0.00327	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000167	0.00327	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—ENO2—muscle cancer	0.000157	0.00309	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—MED12—muscle cancer	0.000144	0.00282	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—MED12—muscle cancer	0.000132	0.00258	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—FH—muscle cancer	0.000131	0.00258	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—ENO2—muscle cancer	0.000131	0.00257	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—FOXO1—muscle cancer	0.00013	0.00255	CbGpPWpGaD
Bezafibrate—PPARA—Circadian rythm related genes—TP53—muscle cancer	0.000128	0.00252	CbGpPWpGaD
Bezafibrate—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000127	0.00249	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000123	0.00242	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—MED12—muscle cancer	0.000121	0.00238	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—ENO2—muscle cancer	0.00012	0.00235	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000105	0.00205	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000103	0.00201	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9.58e-05	0.00188	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—MED12—muscle cancer	9.43e-05	0.00185	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.38e-05	0.00184	CbGpPWpGaD
Bezafibrate—PPARG—Circadian rythm related genes—TP53—muscle cancer	9.2e-05	0.0018	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—ENO2—muscle cancer	8.6e-05	0.00169	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—VEGFA—muscle cancer	8.28e-05	0.00162	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—FH—muscle cancer	8.24e-05	0.00162	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—FH—muscle cancer	7.55e-05	0.00148	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—MED12—muscle cancer	7.43e-05	0.00146	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—ENO2—muscle cancer	6.77e-05	0.00133	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.72e-05	0.00132	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—VEGFA—muscle cancer	5.93e-05	0.00116	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—PTGS2—muscle cancer	5.48e-05	0.00108	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.29e-05	0.00104	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—MED12—muscle cancer	4.65e-05	0.000913	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—PTGS2—muscle cancer	4.57e-05	0.000896	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—MED12—muscle cancer	4.27e-05	0.000837	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—ENO2—muscle cancer	4.24e-05	0.000832	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—PTGS2—muscle cancer	4.18e-05	0.00082	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—FH—muscle cancer	4.05e-05	0.000795	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—ENO2—muscle cancer	3.89e-05	0.000763	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.32e-05	0.000651	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.04e-05	0.000597	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—PTGS2—muscle cancer	2.99e-05	0.000587	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—PTGS2—muscle cancer	2.36e-05	0.000463	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—MED12—muscle cancer	2.29e-05	0.000449	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—ENO2—muscle cancer	2.09e-05	0.00041	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—PTGS2—muscle cancer	1.48e-05	0.00029	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—PTGS2—muscle cancer	1.35e-05	0.000266	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—PTGS2—muscle cancer	7.27e-06	0.000143	CbGpPWpGaD
